Floatz logo

Zovostotug

Leiomyosarcoma

OncoResponse, Inc.monoclonal_antibodyPhase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

17 Active assets in the Leiomyosarcoma cohort.

Asset / SponsorPhaseRating
Sorafenib
National Cancer Institute (NCI)
Phase 2B
Temsirolimus
National Cancer Institute (NCI)
Phase 2B
Cixutumumab
National Cancer Institute (NCI)
Phase 2B
vx-970
Massachusetts General Hospital
Phase 2B
Cediranib
University Health Network, Toronto
Phase 2CCC

View all 26 →

Same molecule, other indications

Zovostotug is also rated in:

liposarcomaDormant
CC
Indicative ·
47 / 100
View asset →
neoplasmDormant
CC
Indicative ·
45 / 100
View asset →
metastatic malignant neoplasmDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →